Prosecution Insights
Last updated: November 04, 2026
Application No. 18/775,374

LYOPHILIZED METOLAZONE FORMULATION FOR PARENTERAL ADMINISTRATION

Non-Final OA §103
Filed
Jul 17, 2024
Priority
Jul 24, 2023 — provisional 63/515,327
Examiner
COHEN, MICHAEL P
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hyloris Developments SA
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
510 granted / 865 resolved
-1.0% vs TC avg
Strong +27% interview lift
Without
With
+27.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
917
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
51.6%
+11.6% vs TC avg
§102
12.9%
-27.1% vs TC avg
§112
19.6%
-20.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 865 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-19, and the species of a “metolazone lyophilizate kit,” reading on claims 13-19, in the response dated 6/9/2026, is acknowledged. Claims 1-12 and 20-23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species (claims 1-12), or a nonelected invention (claims 20-23), there being no allowable generic or linking claim. Claim Status Claims 1-23 are pending. Claims 1-12 and 20-23 are withdrawn. Claims 13-19 are examined on the merits in this prosecution. CLAIM REJECTIONS Obviousness Rejection The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 1) Claims 13 and 19 are rejected under 35 U.S.C. 103 as being unpatentable over Lim (US 10,857,097), in view of Shirode (WO 2012038371 A1), Biringer (US 5,124,152), and Amin (“Lyophilization of Polyethylene Glycol Mixtures,” Journal of Pharmaceutical Sciences, Vol. 93, NO. 9, September 2004, 2244-2249). Lim teaches a solid dosage of an orally-dosed biologically active material comprising at least one biologically active material and at least one “matrix forming agent,” reading on the limitation of “a bulking agent.” Lim teaches the dosage form is produced by freeze-drying the biologically active agent and the matrix forming agent from water (col 25: 6-40). Lim also teaches a kit including these ingredients (Abstract). For claim 13, Lim teaches a container or kit component comprising an active agent such as metolazone (col 12: 12) and a matrix forming agent such as mannitol (col 16: 42-49). Lim teaches the pH of the mixture is adjusted to a pH of preferably between 6.4 and 7.8 (col 26: 13-16), within the claimed range. Because the claimed range overlaps with the range disclosed by the prior art, a prima facie case of obviousness exists. Lim also teaches the pH can be controlled by the addition of a buffer such as sodium hydrogen carbonate, sodium carbonate, or sodium hydrogen phosphate (col 26: 18-21). While Lim does not teach the buffer in a second container, one of ordinary skill in the art would place the buffer in the second container due to the presence of water to maintain the buffer in solution. While Lim teaches a kit comprising a solid dosage form comprising a biologically active material and at least one matrix forming agent (col 4: 19-25), Lim does not teach a second container comprising a pharmaceutically acceptable diluent. Furthermore, Lim does not teach the limitation of a solubilizer. Shirode and Biringer teach the missing elements of Lim. Shirode teaches a kit containing a first container comprising a lyophilized formulation and a second container containing a diluent for reconstituting the lyophilized formulation (pg 5: 12-16). It is noted that the active agent of Shirode is not metolazone, but the general arrangement of the elements is that claimed instantly. Biringer teaches compositions of comprising metolazone and a solubilizer such as PEG 400, where the metolazone is present in the amount of 0.25-5 mg/mL in the final aqueous solution and polyethylene glycol 400 is present in the amount of 25-50% v/v in the final solution (Abstract; col 2: 36-42). For claim 19, none of the prior art of Lim, Shirode, and Biringer teach or suggest addition of tert-butanol in the composition. Amin teaches Amin teaches that addition of PEG 400 to commonly used bulking agents, such as mannitol, sucrose, or polyvinylpyrrolidone, caused a significant change in the thermal properties of the bulking agents as observed by modulated differential scanning calorimetry (Abstract), indicating an interaction between the substances. Amin further teaches that freeze drying microscopy studies indicated that lyophilization of PEG 400 with mannitol is not feasible at temperatures above -50 oC because of structure collapse or lack thereof within the lyophilized sample pg 2247, left column). Biringer teach or suggest addition of tert-butanol in the composition. Amin further teaches the low temperature lyophilization system eliminates the need for adding tert-butanol (pg 2249, left column top). The skilled artisan would have expected success in substituting Shirode's two container kit for the single container kit of Lim since the two container kit maintains a separation between the lyophilized dry components of metolazone and the bulking agent, and the diluent comprising a solubilizer such the PEG 400 solubilizer, taught by Biringer, a buffer, and water since Amin teaches that the combination of PEG 400 to mannitol causes an interaction between the substances and lyophilization must be carried out at very low temperatures to avoid collapse of the structure of the lyophilized material. 2) Claim 14 is rejected under 35 U.S.C. 103 as being unpatentable over Lim (cited above), in view of Shirode (cited above) Biringer (cited above), Amin (cited above), and Stratis (US 10,703,532) The teachings of Lim, Shirode, Biringer, and Amin are discussed above. The combination of Lim, Shirode, Biringer, and Amin does not teach a connector between the first and second containers. Stratis teaches the missing element of the combination of Lim, Shirode, Biringer, and Amin. Stratis teaches a system and method for mixing compounds utilizing a transfer device that allows for diluent from a syringe to be introduced in a sterile manner into a container comprising a powder comprising a drug substance (Abstract). See Fig. 1, Step 2, and Fig. 2, Step 2, below. PNG media_image1.png 759 220 media_image1.png Greyscale PNG media_image2.png 667 332 media_image2.png Greyscale Fig. 1, Step 2 Fig. 2, Step 2 The skilled artisan would have expected success in utilizing the connector taught by Stratus to connect the first and second container taught by the combination of Lim, Shirode, Biringer, and Amin because Stratis teaches the connector between the two containers allows sterile transfer of, for example, the contents of the second container into the first container. 3) Claim 15 is rejected under 35 U.S.C. 103 as being unpatentable over Lim (cited above), in view of Shirode (cited above), Biringer (cited above), Amin (cited above), and Ali (“Kolliphor® HS 15 - An Enabler for Parenteral and Oral Formulations,” American Pharmaceutical Review, February 25, 2019, 1-25). The teachings of Lim, Shirode, Biringer, and Amin are discussed above. The combination of Lim, Shirode, Biringer, and Amin does not teach the presence of macrogol-15-hydroxystearate in the diluent. Ali teaches the missing element of the combination of Lim, Shirode, Biringer, and Amin. Ali teaches Kolliphor® HS 15, an alternative name for macrogol-15-hydroxystearate, is an “excellent solubilizer with unparalleled attributes leading to a safe administration of oral and injectable drug molecules” (pg 17, Conclusion), and the combination of macrogol-15-hydroxystearate and polyethylene glycol 400 was safe for administration in rats and dogs (pg 14, top partial paragraph). Regarding the limitation of 2-4% w/v of macrogol-15-hydroxystearate, MPEP 2144.05(II) is cited: “It is a settled principle of law that a mere carrying forward of an original patented conception involving only change of form, proportions, or degree, or the substitution of equivalents doing the same thing as the original invention, by substantially the same means, is not such an invention as will sustain a patent, even though the changes of the kind may produce better results than prior inventions."). Furthermore, modifying the amounts of a solubility enhancing substance to optimize the amount of the enhancer is a technique known to an ordinarily skilled practitioner. See MPEP 2143(I)(D). 4) Claims 16-18 are rejected under 35 U.S.C. 103 as being unpatentable over Lim (cited above), in view of Shirode (cited above), Ali (cited above), Biringer (cited above), Amin (cited above), and the Medline Monograph on Metolazone (“Zaroxolyn®”, available on the Internet Aug 11, 2015; downloaded 8-14-2026 from https://reference.medscape.com/drug/zaroxolyn-metolazone-342416; cited hereinafter as the “Medline Monograph”). The teachings of Lim, Shirode, Biringer, and Amin are discussed above. The combination of Lim, Shirode, Biringer, and Amin does not teach the amount of metolazone in the lyophilizate composition. The Medline Monograph teaches the missing element of the combination of Lim, Shirode, Biringer, and Amin. The Medline Monograph teaches dosages of metolazone are 2.5, 5, and 10 mg, respectively (pg 1). For claims 16 and 17, Lim teaches the amount of active agent may be 5 mg, and may comprise 1-45% of the composition (col 15: 14-22), and mannitol may comprise from about 5% to about 80% of the composition (col 16: 42-49). As such, the amounts claimed in claims 16 and 17 of metolazone and mannitol overlap with those of Lim. Lim also teaches a pH range of preferably between 6.4 and 7.8 (col 26: 13-16), overlapping the range claimed in each of claims 16 and 17. For the diluent in claim 16, Biringer teaches polyethylene glycol 400 is present in the amount of 25-50% v/v in the final composition, overlapping the claimed range, and Lim teaches a phosphate buffer (col 17: 40-44). For claim 18, it is noted that Biringer teaches compositions of comprising metolazone and a solubilizer such as PEG 400, where the metolazone is present in the amount of 0.25-5 mg/mL in the final aqueous solution and polyethylene glycol 400 is present in the amount of 25-50% v/v in the final solution (Abstract; col 2: 36-42). For the 5 mg dose taught by the Medline Monograph, the Examiner calculates an amount of diluent required is 1.0 to 20 mL, overlapping the claimed range. CONCLUSION Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL P COHEN whose telephone number is (571)270-7402. The examiner can normally be reached on M-Th 8:30-5:30; F 9-4. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup, can be reached on (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL P COHEN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jul 17, 2024
Application Filed
Aug 19, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778883
GASTRIC RESIDENCE SYSTEMS FOR ADMINISTRATION OF ACTIVE AGENTS
4y 6m to grant Granted Nov 03, 2026
Patent 12779047
LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE
4y 1m to grant Granted Nov 03, 2026
Patent 12778129
INSECT ATTRACTANT AND KILLING SYSTEM
1y 11m to grant Granted Nov 03, 2026
Patent 12766102
LIPOSOMES AND METHODS OF MAKING THE SAME
4y 3m to grant Granted Oct 20, 2026
Patent 12758578
ANTI-INFLAMMATORY DENDRIMER FORMULATION FOR THE TREATMENT OF PSORIASIS
4y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
86%
With Interview (+27.3%)
2y 11m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 865 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month